Webinar Highlights: Using Patient-Derived 3D Cell Culture Models for Semi-Automated Drug Screening

Discover methods to advance the pre-clinical development of novel anti-cancer compounds

Dr. Christian Regenbrecht, Founder and CEO, Cellular Phenomics & Oncology (CPO), recently shared expert insights into how comprehensive patient-derived 3D cell culture models can be integrated into the pre-clinical development of novel anti-cancer compounds. Watch the SelectScience® webinar to learn about the benefits of using these cell cultures over adherent 2D cell lines, how they can be incorporated into a workflow for high-throughput screening, and examples of the use of patient-derived cell culture models in personalized oncology.




Beyond Genomics

Multiplex-Analyse von Proteinen und Phosphoproteinen

Eine neue Methode des Multiplex-Protein-Profiling bietet vielschichtige Anwendungsmöglichkeiten: Sie reichen von mechanistischen Studien der Wirkweise von Arzneimittelkandidaten, über Biomarkerforschung und prädiktive Toxikologie bis hin zur personalisierten Onkologie. 




MAY 2nd

Entrepreneurs, Academics & Entrepreneurial Academics succeed in Berlin

With Berlin's plethora of life science research and academia, opportunities abound for biotech entrepreneurs. Here's how the city bridges the gap between science and business!

[...] One contestant of the first Speed Lecture Award in 2008, Christian Regenbrecht, was a postdoc at the Max Planck Institute for Molecular Genomics, and he ultimately turned it into his startup, Cellular Phenomics & Oncology (CPO). "I was working on Oncotrack, an initiative backed by the big pharmas like Eli Lilly, Bayer and Pfizer to explore the next generation of oncology biomarkers, with a team at Charité when I was inspired to start my company," he recalls. [...]



MARCH 30th

How to Find the Missing Link between Genotype & Phenotype

Even if you have a protein profile, you still need its activation pattern. A new technology of bead-based phosphoprotein immunoassays can map a lot of them.

[...] CPO, a biotech company based in Berlin, applied DigiWest in the context of their primary patient-derived 3D cell models (PD3Ds), which they use to test drug candidates. The company sent samples to NMI TT, who then analyzed 122 total and phospho-proteins in different patient tumor-derived cell models. The result? NMI TT characterized individual and distinct protein signatures that CPO can now combine with further drug testing and NGS sequencing to eventually identify individualized precision therapies. [...]